Quantcast
Channel: stem cell biotech Archives - The Niche
Browsing latest articles
Browse All 21 View Live

Shot to the heart: J&J punts on Capricor & its cardiac stem cell program

How is the stem cell and regenerative medicine biotech sector doing these days and does recent news about specific biotechs such as Capricor suggest issues for the sector more broadly? Capricor had bad...

View Article


Top 20 predictions for stem cells & regenerative medicine in 2018

Every year I look into my stem cell crystal ball and make predictions for our field including regenerative medicine. Well, I don’t really look into a crystal ball, but I try to use a combination of...

View Article


Stem cell company Intellicell facing new financial wrinkles

It’s difficult to make it as a biotech company and I would say stem cell biotechs in general may have an even rougher time. One such company,  Intellicell (Intellicell Biosciences, Inc), is showing a...

View Article

Top 20 Stem Cell Predictions for 2015

Every year I do a list of top predictions for the coming year for the stem cell and regenerative medicine field. For example, you can see past top 10 predictions lists for 2013 and 2014. What’s in...

View Article

At mid-year, how are my top 20 stem cell predictions for 2015 doing?

Each year towards the end of December I make predictions for the coming year as I did for 2015. In the past I usually make a top 10 prediction list, but for this year I made 20 predictions. Admittedly...

View Article


Mesoblast stock on hold: Poll if you expect good or bad news

Adult stem cell biotech Mesoblast ($MESO) is in the unusual situation currently of having its stock on hold. This is a relatively rare event and usually portends some kind of major news. The hold is...

View Article

What is your favorite stem cell/regen med biotech & why?

I’m putting together a list of stem cell and regenerative medicine biotech companies for a blog post, including both public and private. I’ve got a good list already, but want it to be fairly...

View Article

FDA Regenerative Medicine Advanced Therapy RMAT designations jump to 36

This post includes my updated list of firms/products that have received FDA regenerative medicine advanced therapy designation or RMAT, which are in the public domain. The numbers really jumped in the...

View Article


Stem Cell Biotech Advanced Cell Technology (ACT) gets $35 million

Advanced Cell Technology (ACT; stock symbol ACTC) announced that it has secured $35 million in funding from investment company, Lincoln Park Capital. The press release quotes CEO Gary Rabin: “We are...

View Article


Why Lanza and I sold ACT stock

It wasn’t so long ago that I did a post explaining why after following the company for years, I finally bought a small amount of stock in the stem cell biotech, Advanced Cell Technology (ACT; symbol...

View Article
Browsing latest articles
Browse All 21 View Live